Zydus Cadila, an innovative global pharmaceutical company, has received tentative approval from USFDA for Aripiprazole Orally Disintegrating Tablets in the strengths of 10 mg, 15 mg, 20 mg and 30 mg. The drug is an anti-phychotic medication used in the treatment of schizophrenia.
Recently, the company entered into a settlement and license agreement with Somaxon Pharmaceuticals, and ProCom One to resolve pending patent litigation involving Silenor (Doxepin) 3 mg and 6 mg tablets.
Flagship company of Zydus Cadila Group, it focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.
DISCLAIMER: Accord Fintech provides the Content on “AS IS” basis without any express or implied warranties. Accord Fintech does not warrant the accuracy, timeliness, completeness, adequacy, merchantability, or fitness for a particular purpose of the Content, and Accord Fintech shall not be liable to Licensee or to any third party with respect to any actual or alleged inaccuracy, untimeliness, incompleteness, inadequacy, unmerchantbailty or unfitness.
Copyright 2012 Accord Fintech Pvt. Ltd., distributed by Contify.com